{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-027432","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.940366+00:00","generated_at":"2026-05-31T08:15:43.345574+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Monopar receives HREC clearance in Australia for Phase 1 trial of MNPR-101-Lu in advanced cancers","bullets":["HREC clearance in Australia to commence Phase 1 therapeutic trial of MNPR-101-Lu (Lu-177 with anti-uPAR antibody).","Trial will enroll patients with advanced solid cancers, including triple negative breast and pancreatic cancer.","Preclinical data showed complete tumor elimination in human pancreatic cancer xenograft model after single injection.","MNPR-101-Lu is a therapeutic follow-on to the ongoing MNPR-101-Zr imaging and dosimetry trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-027432","json":"https://secwatch.observer/filing/0001437749-24-027432.json","markdown":"https://secwatch.observer/filing/0001437749-24-027432.md","text":"https://secwatch.observer/filing/0001437749-24-027432.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924027432/0001437749-24-027432-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924027432/mnpr20240820_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:15:43.345574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}